Compare Microchip Technology Inc. (MCHP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Mesoblast Limited — how do they compare? Microchip Technology Inc. trades at $82.15 (market cap $43.99B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Microchip Technology Inc. is far larger — about 19.9× Mesoblast Limited's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MCHP | MESO | |
|---|---|---|
Market Cap | $43.99B | $2.21B |
Sector | Technology | Technology |
52-Week High | $102.97 | $20.96 |
52-Week Low | $49.02 | $12.88 |
Enterprise Value | $49.12B | $2.21B |
Dividend Yield | 2.25% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
